Q - Adaptive Biotechnologies
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
ADPT$29.36-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net loss | $(25,593) | $(46,248) | $(55,423) | $(93,781) |
| Other comprehensive loss | ||||
| Change in unrealized gains and losses on investments | (61) | (76) | (93) | (397) |
| Comprehensive loss | (25,654) | (46,324) | (55,516) | (94,178) |
| Add: Comprehensive (income) loss attributable to noncontrolling interest | (21) | 26 | (43) | 52 |
| Comprehensive loss attributable to Adaptive Biotechnologies Corporation | $(25,675) | $(46,298) | $(55,559) | $(94,126) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.